Search
Home
News
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Coins2Day 500
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
Dan Primack
Stay informed with Dan Primack’s coverage and analysis for Coins2Day.
Page 19 of 100
Finance
Term Sheet — Thursday, May 6
By
News Correspondent
Finance
Harvard-Linked VC Fund Goes Up in Smoke and Acrimony
By
Tech Reporter
Finance
Term Sheet — Wednesday, May 4
By
Blockchain Reporter
Finance
Term Sheet — Tuesday, May 3
By
Staff Writer
Tech
Dell-EMC Reveals Its New Name
By
News Correspondent
New VC Firm Wants Common Stock, Not Preferred
By
Blockchain Reporter
Finance
Big Healthcare Companies Pump $220 Million into VC Firm
By
Tech Reporter
Finance
Venture Capitalist Quits To Become Middle-School Math Teacher
By
Crypto Correspondent
Finance
Term Sheet — Monday, May 2
By
Blockchain Reporter
Finance
Term Sheet — Friday, April 29
By
Trading Desk
Finance
Carl Icahn Says He Sold All His Apple Stock
By
News Correspondent
Finance
Fidelity’s ‘Unicorn’ Valuations Were Just Proven To Be Bogus
By
Contributing Writer
Finance
Term Sheet — Thursday, April 28
By
Blockchain Reporter
How Reddit Plans To Become a ‘Real’ Business
By
Financial Writer
Finance
AbbVie Buying Cancer Drug Startup Stemcentrx for $10.2 Billion
By
Senior Editor